Polaris Pharmacy Services Named Exclusive U.S. Distributor of AstraZeneca’s FluMist® Home Service—The World’s First At-Home Nasal Spray Flu Vaccine
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Polaris Pharmacy Services, a leading provider of long-term care and specialty pharmacy solutions, has been selected as the exclusive U.S. distributor for FluMist® Home, AstraZeneca’s at-home flu vaccine service available for the 2025-2026 flu season. Through FluMist Home, individuals can order FluMist online to be delivered directly to their home on a date they choose—no doctor’s visit or needle required. The program is the first of its kind to receive FD
Related Questions
How will the exclusive U.S. distribution deal for FluMist® Home affect AstraZeneca’s (AZN) revenue and earnings guidance for the 2025‑2026 flu season?
What are the potential market adoption rates for an at‑home nasal spray flu vaccine compared to traditional flu shots, and how might that influence Polaris Pharmacy Services’ valuation?
Are there any regulatory, supply chain, or competitive risks that could delay or limit the rollout of FluMist® Home and impact the stock performance of both companies?